Vanda Pharmaceuticals (STU:VM4) Long-Term Debt: €0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:VM4 Vanda Pharmaceuticals Inc STU:VM4
72 GF Score
Price €5.12
GF Value €4.85
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Long-Term Debt?

Vanda Pharmaceuticals STU:VM4 -2.48% 72 Long-Term Debt is €0.0 Mil as of Mar. 2026. GuruFocus rates STU:VM4 with a GF Score™ of 72/100 and a GF Value™ of €4.85 (Fairly Valued). The stock has 4 warning signs investors should review.

Vanda Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2026 was €0.0 Mil.

Vanda Pharmaceuticals  (STU:VM4) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Vanda Pharmaceuticals Long-Term Debt Related Terms

Vanda Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Long-Term Debt Chart

Vanda Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vanda Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:VM4
72GF Score
Vanda Pharmaceuticals Inc STU:VM4
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €0.0 Mil mean?
Vanda Pharmaceuticals (STU:VM4) has a Long-Term Debt of €0.0 Mil as of Mar. 2026.
Is Vanda Pharmaceuticals' Long-Term Debt too high?
Vanda Pharmaceuticals' current Long-Term Debt is €0.0 Mil. Overall, Vanda Pharmaceuticals has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Long-Term Debt compare to AVIR and OABI?
Vanda Pharmaceuticals' Long-Term Debt of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Vanda Pharmaceuticals's current Long-Term Debt is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (STU:VM4) is currently considered Fairly Valued. The stock's GF Value™ is €4.85, compared to a current price of €5.12 — trading 5.5% above its estimated fair value. The current Long-Term Debt is €0.0 Mil. Vanda Pharmaceuticals' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Vanda Pharmaceuticals (STU:VM4), the current Long-Term Debt is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanda Pharmaceuticals (STU:VM4) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued. The current stock price of €5.12 is trading 5.5% above its estimated GF Value™ of €4.85. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for STU:VM4:

  • Long-Term Debt: €0.0 Mil
  • GF Value™: €4.85 vs. price of €5.12 (5.5% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the STU:VM4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanda Pharmaceuticals Business Description

Other Exchanges VNDA:USA0LKB:UK
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
72GF Score

Get the complete analysis for STU:VM4

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.12
Price
€4.85
GF Value